Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461543 | 0.83 | MEN1 (0.56) | MEN1KMT2ATDP1MAOATHRB | |
| SCHEMBL13557889 | 0.82 | MEN1 (0.53) | MEN1KMT2ATDP1MAOATHRB | |
| SCHEMBL17376561 | 0.81 | MEN1 (0.51) | MEN1KMT2ATDP1MAOATHRB | |
| SCHEMBL13573531 | 0.80 | EPHX2 (0.45) | MEN1KMT2ATDP1SMN1; SMN2LMNA | |
| SCHEMBL26130165 | 0.80 | MEN1 (0.50) | MEN1KMT2ATDP1MAOATHRB | |
| SCHEMBL10547018 | 0.80 | KMT2A (0.59) | MEN1KMT2ATDP1MAOAMAPT | |
| SCHEMBL7684046 | 0.80 | TPSAB1 (0.44) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL3926325 | 0.79 | SLC6A2 (0.54) | MEN1KMT2ATDP1MAOATHRB | |
| SCHEMBL4588005 | 0.79 | MEN1 (0.52) | MEN1KMT2ATDP1MAOATHRB | |
| SCHEMBL15114181 | 0.79 | MEN1 (0.58) | MEN1KMT2ATDP1MAOASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709519-A1 | PRE-TREATED ION EXCHANGE RESIN FOR ALTERNATIVE ENERGY POWER SOURCE HEAT TRANSFER SYSTEMS WITH LOW CONDUCTIVITY COOLANT REQUIREMENTS | CCI North America Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2025-08-21 | — | — | US | disclosed |
| US-20250057957-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4504724-A1 | SPLEEN TYROSINE KINASE INHIBITORS | Uniquest Pty Limited (AU) | 2025-02-12 | — | — | EP | disclosed |
| CN-119325474-A | Spleen tyrosine kinase inhibitors | 尤尼奎斯特公司 | 2025-01-17 | — | — | CN | disclosed |
| EP-4483875-A2 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240375095-A1 | PRE-TREATED ION EXCHANGE RESIN FOR ALTERNATIVE ENERGY POWER SOURCE HEAT TRANSFER SYSTEMS WITH LOW CONDUCTIVITY COOLANT REQUIREMENTS | CCI NORTH AMERICA CORPORATION | 2024-11-14 | — | — | US | disclosed |
| WO-2024233995-A1 | PRE-TREATED ION EXCHANGE RESIN FOR ALTERNATIVE ENERGY POWER SOURCE HEAT TRANSFER SYSTEMS WITH LOW CONDUCTIVITY COOLANT REQUIREMENTS | CCI NORTH AMERICA CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-3454862-B1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-12048748-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20140005188-A1 | PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2014-01-02 | — | — | US | disclosed |
| EP-2513069-A1 | ANTIFUNGAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-10-04 | — | — | US | disclosed |
| WO-2012123312-A1 | PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012123312-A1 | PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | WO | disclosed |
| WO-2011072345-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-06-23 | — | — | WO | disclosed |
| CN-101015084-B | Treated ion exchange resins, method of making, assemblies and heat transfer systems containing the same, and method of use | HONEYWELL INT INC | 2010-10-27 | — | — | CN | disclosed |
| EP-2146693-A2 | SOLIFENACIN COMPOSITIONS | Dr. Reddy's Laboratories Ltd. (IN) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008128028-A2 | SOLIFENACIN COMPOSITIONS | DR. REDDY'S LABORATORIES LTD. (IN) | 2008-10-23 | — | — | WO | disclosed |
| CN-101015084-A | Treated ion exchange resins, method of making, assemblies and heat transfer systems containing the same, and method of use | HONEYWELL INT INC (US) | 2007-08-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005188-A1 | PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS | SYK, BTK, LCK | MEN1 3382/4885KMT2A 1092/4885TDP1 2827/4885 |
| US-20250057957-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | MEN1 1630/4885KMT2A 2852/4885TDP1 3690/4885 |
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | LCK, BTK, SYK | MEN1 3587/4885KMT2A 1216/4885TDP1 947/4885 |
| US-12048748-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | MEN1 1630/4885KMT2A 2852/4885TDP1 3690/4885 |
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | ERG28, DPM1, CYP51A1 | MEN1 447/4885KMT2A 4333/4885TDP1 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.